<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01768429</url>
  </required_header>
  <id_info>
    <org_study_id>ALFAKALA</org_study_id>
    <nct_id>NCT01768429</nct_id>
  </id_info>
  <brief_title>The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism</brief_title>
  <official_title>The Effect of n-3 Fatty Acids and Fish on Glucose and Lipid Metabolism in Subjects With Impaired Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Eastern Finland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VTT Technical Research Centre, Finland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Eastern Finland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to examine whether the sources of n-3 fatty acids and fish itself
      differ in their effects on glucose metabolism, lipid metabolism, blood pressure, and serum
      inflammatory markers. Lipidomic profiles and gene expression will be used for thorough
      assessment of the possible clinical changes. The study will compare the effects of
      alpha-linolenic acid containing vegetable oil, fatty fish, lean fish and control diet. The
      results of this project will help to identify the optimal source of n-3 fatty acids, and
      reveal the significance of the components of fish other than fatty acids. These data will be
      useful both nationally and internationally, since highly controlled dietary interventions
      utilizing new methodology are scarce.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose metabolism assessed by oral glucose tolerance test and frequently sampled intravenous glucose tolerance test</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>change in glucose metabolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum lipid profile</measure>
    <time_frame>Baseline and at 12 weeks</time_frame>
    <description>Change in serum lipid profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum inflammatory markers</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Change in serum inflammatory markers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and adipose tissue lipidomic profile</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in plasma and adipose tissue lipidomic profile</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma and urine metabonomics</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in plasma and urine metabonomics</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression in adipose tissue and peripheral blood mononuclear cells</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in gene expression in adipose tissue and peripheral blood mononuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reverse cholesterol transport</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Change in reverse cholesterol transport</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Fatty fish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four fatty fish meals per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean Fish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Four lean fish meals per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Alpha-linolenic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 g of alpha-linolenic acid daily from camelina sativa oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Limited fish and alpha-linolenic acid intake</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Fatty fish</intervention_name>
    <arm_group_label>Fatty fish</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Lean Fish</intervention_name>
    <arm_group_label>Lean Fish</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Alpha-linolenic acid</intervention_name>
    <arm_group_label>Alpha-linolenic acid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <arm_group_label>Control diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 40-70 years

          -  BMI 25-32 kg/m2

          -  fasting plasma glucose 5.6-7.0 mmol/l

          -  2 h plasma glucose in oral glucose tolerance test &lt;=11 mmol/l

          -  fasting serum total cholesterol &lt;=7 mmol/l

          -  fasting serum LDL cholesterol &lt;=5 mmol/l

          -  fasting serum triglycerides &lt;=4 mmol/l

        Exclusion Criteria:

          -  any chronic disease or condition that hamper the ability to follow dietary
             intervention

          -  chronic liver, thyroid or kidney disease

          -  alcohol abuse

          -  diabetes

          -  recent weight loss

          -  recent myocardial infarction

          -  corticosteroid therapy

          -  psychiatric disorders which need drug treatment

          -  cancer under treatment

          -  fish allergy or other extensive food allergies

          -  exceptional diets (like Atkin's or vegan diet)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arja Erkkil√§, Adjunct Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ursula Schwab, Adjunct Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Eastern Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Eastern Finland</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 11, 2013</study_first_submitted>
  <study_first_submitted_qc>January 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2013</study_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

